Karsten Lindhardt, MSc, PhD, DBE

CEO at Biograil

Speaker

Karsten has more than 25 years of experience in the pharmaceutical/medtech industry (the last 15 as an executive). He is the CEO and founder of Biograil developing a drug delivery technology for effective oral delivery of biomacromolecules and has established collaborations with Eli Lilly and CSL Behring. Karsten started to explore this technology with his team when he was CSO of Egalet where he was also part of the executive management team making a successful IPO on NASDAQ NYC. Karsten and the team were responsible for the world’s first injection molded oral product Arymo ER to get FDA approval. Karsten has through his career worked in various biotech and pharma companies (Biograil, Egalet, Curalogic, Prosidion, Ferring and Novo Nordisk) and has been involved in API upscaling, formulation development, pre-clinical screening and toxicology, phase 1, 2 and 3 clinical development, new drug application approvals and launch. Karsten is also the co-founder of Scantox, a non-clinical CRO and panel member of Innovation Fund Denmark.